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ABSTRACT
The mechanism of resistance of hepatocellular carcinoma (HCC) to sorafenib 
is unknown and no useful predictive biomarker for sorafenib treatment has been 
reported. Accordingly, we established sorafenib-resistant HCC cells and investigated 
the underlying mechanism of resistance to sorafenib. Sorafenib-resistant cell lines 
were established from the HCC cell line PLC/PRF5 by cultivation under continuous 
exposure to increasing concentration of sorafenib. The IC50 values of the 2 resistant 
clones PLC/PRF5-R1 and PLC-PRF5-R2 were 9.2±0.47 μM (1.8-fold) and 25±5.1 
μM (4.6-fold) respectively, which were significantly higher than that of parental 
PLC/PRF5 cells (5.4±0.17 μM) (p<0.01 respectively), as determined by MTT assay. 
Western blot analysis of signal transduction-related proteins showed no significant 
differences in expression of AKT/pAKT, mTOR/pmTOR, or ERK/pERK between the 
2 resistant clones versus parent cells, suggesting no activation of an alternative 
signal transduction pathway. Likewise, when expression of membrane transporter 
proteins was determined, there were no significant differences in expression levels of 
BSEP, MDR1, MRP2, BCRP, MRP4 and OCT1 between resistant clones and parent cells. 
However, the expression levels of MRP3 in the 2 resistant clones were significantly 
higher than that of parent cells. When MRP3 gene was knocked down by siRNA in PLC-
PRF5-R2 cells, the sensitivity of the cells to sorafenib was restored. In the analysis 
of gene mutation, there was no mutation in the activation segment of Raf1 kinase in 
the resistant clones. Our data clearly demonstrate that the efflux transporter MRP3 
plays an important role in resistance to sorafenib in HCC cells.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third-
leading cause of cancer-related death worldwide [1]. 
Most patients with HCC are diagnosed at an advanced 
stage, when curative therapies, such as surgical resection 
and percutaneous ablation, are of limited utility. Since 
a majority of HCC present intrinsic resistance to many 
cytotoxic anti-cancer agents, interventional treatment 
such as transarterial embolization had been applied for 
advanced HCC [2,3]. Recently, it has been reported that 
sorafenib, a multitargeted tyrosine kinase inhibitor that 
blocks Raf kinase, platelet-derived growth factor receptor 
(PDGFR) and vascular endothelial growth factor receptors 
(VEGFR), significantly improved overall survival in 
patients with advanced HCC in large-scaled multicenter 
phase III trials [4,5]. Therefore, systemic treatment with 
sorafenib is currently recommended for advanced stage 
HCC in the treatment algorithm of HCC worldwide [6]. 
However, the response rate for sorafenib in HCC is very 
low (i.e., 2 - 3%) [4,5].
Abou-Alfa and associates investigated pERK 
expression in HCC tissues by immunohistochemistry, and 
demonstrated that pERK expression is closely associated 
with the effect of sorafenib [7]. This is reasonable because 
sorafenib blocks Raf kinase thereby inhibiting the 
downstream MEK/ERK pathway. However, contradictory 
results have been reported. Patients with high expression 
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of pERK, demonstrated by immunohistochemistry, 
showed significantly shorter overall survivalthan those 
with low expression of pERK [8,9]. Therefore, it remains 
unclear whether pERK is a predictor of the therapeutic 
response to sorafenib in HCC. Thus, no useful predictive 
biomarker for the therapeutic response to sorafenib has 
been identified to date. Chen and associates established 
sorafenib-resistant cell lines from the HCC cell line Huh7 
[10]. They investigated the mechanism of resistance to 
sorafenib in these cells, and demonstrated that the AKT/
mTOR pathway was alternatively activated instead of 
the RAS/RAF/MEK/ERK pathway that was blocked by 
sorafenib in resistant clones. However, it is unknown 
whether or not activation of this alternative pathway is 
entirely responsible for sorafenib resistance.
It is well known that multidrug resistant transporter 
proteins such as MDR1 and MRP2 are overexpressed in 
many kinds of cancer cells that are resistant to anticancer 
drugs. Overexpression of MDR1 has beenreported to be 
associated with resistance to several anticancer drugs 
in hematological malignancies, brain tumors, lung 
cancers, renal cell cancers, and ovarian cancers [11–16]. 
Overexpression of MRP2 is also reportedly associated 
with resistance to anticancer drugs in lung cancers, renal 
cell cancers, bladder cancer and colorectal cancers [17–
20]. Since there are many transporters in hepatocytes, 
including MDR1 and MRP2, it is plausible that 
theiroverexpression is involved in resistance to sorafenib. 
However, there have been no reports that haveinvestigated 
this possible relationship between sorafenib resistance and 
transporter expression. In addition, it has been reported 
that drug resistance to molecular targeting agents is 
sometimes induced by genetic mutation in the targeted 
molecules. The resistance to imatinib in gastrointestinal 
stromal tumors (GISTs)is acquired by a mutation in the 
ATP binding site of c-kit, a molecular target of imatinib 
[21,22]. Similarly, the resistance to gefitinib is acquired 
in lung cancer by a mutation of EGFR gene, a target 
molecule of gefitinib [23,24]. However, there have been 
no reports that have investigated mutations of Raf1 kinase, 
an important target molecule forsorafenib.
Therefore, in this study, we first established 
sorafenib-resistant cell lines, and investigated expression 
of AKT/pAKT and mTOR/pmTOR, key molecules 
in the alternative PIK3/AKT/mTOR pathway. We 
then investigated the expression of several important 
membrane transporter proteins in the resistant cells. We 
finally performed mutational analysis of molecular targets 
of sorafenib in resistant cells.
RESULTS
Resistance of PLC/PRF5-R1 and PLC/PRF5-R2 
clones to sorafenib
We first established a sorafenib-resistant cell line 
(mixed population) from parental PLC/PRF5 cells, and 
isolated 2 sorafenib-resistant clones by using a limiting-
dilution method as described in Materials and Methods. 
We then examined IC50 values of the 2 clones (PLC/
PRF5-R1, PLC/PRF5-R2) by MTT assay (Figure 1). 
The IC50 values for PLC/PRF5-R1 and PLC-PRF5-R2 
were 9.2 ± 0.47 μM (1.8-fold) and 25 ± 5.1 μM (4.6-fold) 
respectively, demonstrating significantly higher values 
than that of parental cells (5.4 ± 0.17 μM) (p<0.01 and 
p<0.01, respectively). Thus, we were able to establish 
sorafenib-resistant clones that showed weak or strong 
resistance to sorafenib.
Figure 1: Resistance of PLC/PRF-R1 and PLC/PRF5-R2 cell lines to sorafenib. The sensitivities of PLC/PRF5-R1, PLC/
PRF5-R2 and PLC/PRF5 cells to sorafenib were assessed by MTT assay. The IC50 values were calculated by non-linear regression analysis.
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Expression of AKT/pAKT and mTOR/pmTOR 
in sorafenib-resistant clones
To examine if the alternative AKT/mTOR 
pathway is activated in the resistant clones, we 
investigated expression of AKT/pAKT and mTOR/
pmTOR in these cells by Western blot analysis (Figure 
2). However, no significant difference was observed in 
the bands for pAKT and AKT between resistant clones 
and parent cells. Likewise, no significant difference 
was observed in the expression of pmTOR and mTOR 
between resistant clones and parent cells. Thus, it 
became evident that the AKT/mTOR signaling pathway 
was not activated in our sorafenib-resistant clones. In 
addition, in the analysis of ERK/pERK expression, 
no significant difference was observed between the 
resistant clones and parent cells.
Up-regulation of MRP3 in sorafenib-resistant clones
We investigated protein expression levels of 
major efflux transporters (BSEP, MDR1, MRP2, 
BCRP and MRP3) and influx transporters (MRP4 
and OCT1) in PLC/PRF5-R1, PLC/PRF5-R2 and 
PLC/PRF5 cells by Western blot analysis (Figure 3). 
There were no significant differences in the bands 
for BSEP, MDR1, MRP2, BCRP, MRP4 and OCT1 
among PLC/PRF5-R1, PLC/PRF5-R2 and PLC/
PRF5 cells. However, the expression level of MRP3 
was higher in PLC/PRF5-R1 and was even higher in 
PLC/PRF5-R2 cells than in PLC/PRF5 cells. Thus, 
the efflux transporter MRP3 was up-regulated in 
sorafenib-resistant clones depending on the strength 
of resistance, suggesting that MRP3 protein transports 
sorafenib outside the cells resulting in acquisition of 
sorafenib resistance.
Knockdown of MRP3 restored sorafenib 
sensitivity
In order to prove that MRP3 is closely associated 
with sorafenib resistance, we knocked down theMRP3 
gene in PLC/PRF5-R2 cells using siRNA and 
investigated the change of sensitivity to sorafenib. The 
relative mRNA levels of MRP3 in the knocked-down 
cells (PLC/PRF5-R2/si) were suppressed to 20% or less 
at 24 – 72 h after transfection of siRNA as compared 
with that of control cells (PLC/PRF5-R2/ra) (Figure 4A). 
The IC50 value of PLC/PRF5-R2/si cells was 7.2 ± 1.9 
μM, which was significantly lower than that of control 
cells (15.9 ± 2.1 μM) (Figure 4B). Thus, knockdown of 
MRP3 in sorafenib-resistant cells restored sensitivity to 
sorafenib, suggesting that MRP3 plays an important role 
for acquisition of resistance to sorafenib.
No mutation in the activation segment of Raf1 
kinase in resistant clones
Since sorafenib blocks the MAP kinase pathway 
mainly by inhibiting Raf1 kinase, we examined if there 
is a mutation in the activation segment of Raf1 kinase 
that involves binding with sorafenib (Figure 5). No 
mutation was detected in any of the sequences of exons 
13 and 14 (activation segment) in the genomic DNA of 
PLC/PRF5-R1 and PLC/PRF5-R2 cells. These sequences 
were completely identical to those of parental cells. This 
suggests that sorafenib- resistance in PLC/PRF5-R1 and 
PLC/PRF5-R2 cells is not induced by mutation of the 
Raf1 gene.
DISCUSSION
In this study, we established 2 sorafenib-resistant 
clones from the HCC cell line PLC/PRF5, and showed 
that themembrane transporter MRP3 was overexpressed 
in these clones. Moreover, knockdown of the MRP3 gene 
in these clones restored sensitivity to sorafenib. These data 
strongly suggest that MRP3 is a novel resistance factor for 
sorafenib. This is the first report showing a close association 
between sorafenib resistance and overexpression of a 
membrane transporter. Chen and associates reported that 
they established 2 sorafenib-resistant clones from theHCC 
cell line Huh7 [10]. Although they did not present IC50 
values of the 2 sorafenib-resistant clones, the values appear 
to be about 10 μM based on the figure from their paper, 
and this represents 2-fold or less resistance relativeto parent 
cells. On the other hand, our 2resistant clones showed 
1.8-fold and 4.6-fold resistance to sorafenib relative to 
parent cells. We believe that resistant cells with at least 
3-fold or more resistance relative toparental cells shouldbe 
used for investigation of drug resistance. Moreover, Chen 
et al. demonstrated that the AKT/mTOR pathway was 
alternatively activated in their resistant clones. However, 
our resistant clones, with 1.8-fold and 4.6-fold resistance, 
did not show any enhancement of AKT/mTOR signals 
(Figure 2). The reason for this difference is unclear butmay 
be due to differences in the cell lines used. Moreover, 
although there no data are available on the expression of 
membrane transporters in their clones, it is possible that 
MRP3 is overexpressed in those cells. Since a majority of 
previous in vitro studies on sorafenib have used the HCC 
cell line PLC/PRF5 [25–27], we used these cells to establish 
sorafenib-resistance cell lines in the present study.
MRP3 is an ATP-binding cassette (ABC) transporter 
that is expressed in the basolateral membrane of hepatocytes 
and effluxes organic ions and glucuronide conjugates into 
the blood [28]. It is known that MRP3 is expressed in normal 
hepatocytes and it is reportedly sometimes overexpressed in 
HCC cells to various degrees [29]. Moreover, it has been 
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Figure 2: Expression of AKT/pAKT, mTOR/pmTOR, and ERK/pERK in sorafenib-resistant cells. The expression of 
pAKT, AKT, pmTOR, mTOR, pERK, and ERK in PLC/PRF5, PLC/PRF5-R1 and PLC/PRF5-R2 cells wasexamined by Western blot 
analysis. β-actin was used as an internal control.
Figure 3: Expression of membrane transporters in sorafenib-resistant cells. Expression of BSEP, MDR1, MRP2, BCRP, 
MRP3, MRP4, and OCT1 in PLC/PRF5, PLC/PRF5-R1 and PLC/PRF5-R2 cells wasexamined by Western blot analysis. β-actin was used 
as an internal control.
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Figure 5: The activation segment sequence of the Raf1 gene in sorafenib-resistant cells. The sequence of the activation 
segment of the Raf1 gene, which comprises exons 13 and 14, in PLC/PRF5, PLC/PRF5-R1 and PLC/PRF5-R2 cells was determined by 
direct sequencing.
Figure 4: Knockdown of the MRP3 gene in PLC/PRF5-R2 cells and resulting change in sensitivity to sorafenib. A. The 
MRP3 gene in PLC/PRF5-R2 cells was knocked down by siRNA. The relative mRNA levels at 24 h, 48 h, 72 h and 96 h were determined 
by Taqman PCR. B. The viabilityof PLC/PRF-R2 cells treated with siRNA or random RNA was assessed by MTT assay.
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reported that MRP3 is involved in resistance to etoposide 
and MTX in ovarian cancer and glioblastoma cells [30,31]. 
Thus, it is plausible that HCC shows resistance to sorafenib 
depending on the extent of MRP3 expression. In fact, 
MRP3 was highly expressed in the HCC tissues that never 
responded to sorafenib treatment (3/5) but not in those that 
responded (0/4) by immunohistochemistry although the 
number of tissues (patients) examined was relatively small 
(Supplementary Figure S1).
Currently sorafenib is approved for the treatment of 
HCC and renal cell carcinoma [32,33]. Since it is known 
that MRP3 is expressed not only in hepatocytes but also 
in renal cells [34], MRP3 may play an important role as a 
resistance factor in renal cell carcinoma.
Sorafenib undergoes oxidative metabolism 
mediated by cytochrome p450 3A4 primarily to sorafenib 
N-oxide [35]. Sorafenib and its oxidized metabolites 
undergo glucuronidation by UGT1A9 in hepatocytes, 
and is either excreted into bile and eliminated via feces 
or into the bloodstream and eliminated via urine [36]. 
However, it is currently unknown which transporters 
excrete glucuronide- sorafenib metabolites into bile or 
blood. MRP3 is a well-known transporter of glucuronide 
conjugates including etoposide and MTX into urine. 
Therefore, our data suggest that glucuronide conjugates 
of sorafenib metabolites are excreted by MRP3 into urine.
Sorafenib was originally developed to inhibit 
Raf1 kinase, and it exhibits a high antitumor activity by 
inhibiting RAF/MEK/ERK signal transduction. Since 
the RAF/MEK/ERK pathway is activated in a majority 
of HCC tissues [37], it is possible that a mutation occurs 
in the Raf1 gene, in particular in its activation segment, 
which is directly involved in binding to sorafenib in 
sorafenib-resistant cells. However, we did not find any 
mutations in thissegment of our sorafenib-resistant clones. 
Moreover, no mutations were detected in the ATP binding 
site of Raf1 kinase in these cells (Supplementary Figure 
S2). It has been reported that secondary mutations of 
the c-kit and EGFR genes confer acquired resistance to 
imatinib in GISTs and gefitinib in lung cancer respectively 
[22,24]. These tumor cells have initialmutations as driver 
gene mutations, whereas HCC has few mutations in the 
Raf1 kinase gene. In addition, sorafenib inhibits not 
only Raf1 kinase but also B-Raf, PDGFR, VEGFR, and 
other tyrosine kinases. In this context, it is reasonable 
that genetic mutation is not involved in the resistance to 
sorafenib, although we cannot rule out thepossibility that 
there are mutations in other tyrosine kinases targeted by 
sorafenib in these resistant clones.
In conclusion, we established 2 sorafenib-
resistant clones (PLC-PRF5-R1 and -R2) from the HCC 
cell line PLC/PRF5. These resistant clones showed 
overexpression of MRP3 but not other membrane 
transporters, and knockdown of MRP3 in the resistant 
clones restored the sensitivity to sorafenib. These results 
strongly suggest that MRP3 is a novel resistance factor 
for sorafenibin HCC cells.
MATERIALS AND METHODS
Cell culture and compounds
The representative human hepatoma cell line, PLC/
PRF5, was purchased from American Tissue Culture 
Collection (ATCC). PLC/PRF5 cells were grown in 
Dulbecco’s Modified Eagles Medium (DMEM, Invitrogen 
Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
FBS, 2mM L-gultamine. Sorafenib (LKT Laboratory, St 
Paul, MN) was dissolved in 100% dimethyl sulfoxide 
(DMSO, Invitrogen Sigma-Aldrich) at 40 mM and stored 
at −20°C.
Establishment of sorafenib-resistant cell line
PLC/PRF5 cells were continuously exposed 
to increasing concentrations of sorafenib over 24 
months. Starting cell culture with 5.4 μM of sorafenib 
concentration (IC50 for PCL/PRF5 cells), the exposure 
dose was increased by 0.5 to 1 μM every month until 
reaching 3 times the IC50 inparent cells. Subsequently, 
cloning was performed by the limiting dilution method.
Cell viability analysis
Cell viability was assessed by using the 
3-(4,5-dimethylthiazol-2yl)-2,5- diphenyl-2H-tetrazolium 
bromide (MTT) assay. In brief, cells were seeded in 96-
well plates (5000 cells/well) and incubated for 24 h at 
37°C. Then, sorafenib was added to the wells at various 
concentrations, and the plates were incubated for another 
72 h at 37°C. MTT dye solution (Sigma-Aldrich, St. 
Louis, MO) was added to the wells, and the plates were 
incubated at 37°C for 4 h, followed by addition of stop 
solution (isopropanol with 0.04 N HCl). Absorbance at 
570 nm was determined on a (Bio-Rad, Hercules, CA) 
plate reader. IC50 values were determined by non-linear 
regression analysis. Values are given as mean ± standard 
deviation of 5 experiments.
Western blot analysis
Cells were washed with phosphate buffered saline 
(PBS) and lysed in lysis buffer (50 mMol/L Tris pH 
8.0, 150 mM NaCl, 0.01% SDS, 1% NP40, 0.5% Na-
desoxycholate, 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4) 
containing protease inhibitors (Sigma-Aldrich). Cell 
lysates were analyzed for protein content, resolved by 
sodium dodecylsulfate-polyamide gel electrophoresis 
(SDS-PAGE), and transferred to polyvinylidene fluoride 
(PVDF) membranes using a semi-dry transfer apparatus 
or wet transfer apparatus (Bio-Rad). Blots were blocked 
with 5% fat-free dry milk in Tris-buffered saline-Tween 
(TBS-T) buffer for 1 h and then incubated overnight 
with rabbit anti-phospho-Akt polyclonal antibody (Cell 
Signaling Technology, Tokyo, Japan), rabbit anti-Akt 
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polyclonal antibody (Abcam, Cambridge, UK), rabbit anti-
mTOR polyclonal antibody (Abcam), rabbit anti-phospho-
mTOR (Abcam) monoclonal antibody, rabbit anti-ERK 
(Cell Signaling Technology) polyclonal antibody, mouse 
anti-phospho-ERK monoclonal antibody (Cell Signaling 
Technology), mouse anti-MDR1 monoclonal antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) monoclonal 
antibody, rabbit anti-MRP2 polyclonal antibody (Cell 
Signaling Technology), rabbit anti-MRP3 polyclonal 
antibody (Novus Biologicals, Littleton, CO), rabbit anti-
MRP4 polyclonal antibody (Cell Signaling Technology), 
rabbit anti-BCRP polyclonal antibody (Sigma-Aldrich), 
rabbit anti-BSEP polyclonal antibody (Sigma-Aldrich), 
and rabbit anti-OCT1 polyclonal antibody (Abcam) 
as primary antibodies. The membranes were washed 
with TBS-T and incubated with secondary horseradish 
conjugated goat anti-mouse antibody (GE Healthcare 
UK Limited, Buckinghamshire, UK). The proteins were 
visualized by standard procedures including an ECL 
detection system (GE Healthcare UK Limited). To ensure 
equal protein loading, the same blot was developed for 
b-actin (Sigma-Aldrich) as a loading control.
Transfection assay
The PCL/PRF5-R2 cells were transiently transfected 
with 30 nM of MRP3 specific small interfering RNA 
(siRNA) or random siRNA as a control using transfection 
reagent (Lipofectamine 2000, Invitrogen) according 
to the manufacturer’s recommendations. After 24 h 
posttransfection, the cells were incubated with sorafenib 
for 48 h, and cell viability was determined by MTT assay. 
The knockdown of MRP3 gene was confirmed by real 
time PCR using Taqman gene expression assay of MRP3 
(Hs00978473_m1, Applied Biosystems, Hitachi, Japan).
Direct sequencing of Raf1 gene activation motif
Genomic DNA was isolated from cells using a 
DNeasy kit (QIAGEN, Hilden, Germany) following the 
manufacturer’s instructions. The activation segment of 
Raf1 kinase encompassing exons 13 and 14 was amplified 
from DNA by PCR with the following primers: forward 
primer 5’-accagagtccttaacaagcattg-3’ and reverse primer 
5’-gacagagccagtaggttgttcaa-3’ for exon 13, and the 
forward primer 5’-agatgtctgtgaggcctgtcata -3’ and reverse 
primer 5’-gatgccataggagtagacatccg-3’ for the exon 14. 
The PCR products were sequenced after purification 
using an ABI PRISM®3100 Genetic Analyzer (Applied 
Biosystems).
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